As for Peter hyping up the Pancreatic data I will disagree but given there is no telling you otherwise I will save my breath on an explanation. Regarding the shelf they didn't really have a lot of time to act from when it was filed to after the pancreatic data was released. In June when the shelf was filed the SP was around $6.30. It was assumed that the company was going to present the pancreatic data at AACR in mid July. Which I can only assume was the reason for the run up to the peak of $8.80 on July 12th. So looking back from June 14th, when the shelf was filed, to July 12th would have been the best time for them to act on that shelf. I certainly don't blame them for not doing so as they had the pancreatic data release upcoming and the start of the AML Phase II by the end of the year. Why issue shares at $8 when you believe the share price will be going higher?
Obviously this didn't play out the way many of us, and the company, thought it would for reasons previously mentioned and looking back it might have been smart of them to tap some of that shelf then but hindsight is 20/20.
News 
Market Data 
Discover 
